⏳ Fetching live dividend data...
Home › Calculator › ETTX Dividend Calculator 2026
Entasis Therapeutics Holdings Inc. · NASDAQ
Price: $2.19 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ETTX → $6.57M in 10 years · $261,416.99/month
Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to advance its portfolio. A licensing and collaboration agreement is in place with Zai Lab (Shanghai) Co., Ltd. for the continued development of durlobactam and SUL-DUR. Additionally, they have a collaborative arrangement with the Global Antibiotic Research and Development Partnership for the development and subsequent commercialization of Zoliflodacin. Established in 2015, Entasis Therapeutics Holdings Inc. maintains its corporate headquarters in Waltham, Massachusetts, and functions as a subsidiary of Innoviva, Inc.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ETTX position with:
Real after-tax yield depends on where you live and how you hold ETTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 91.32% | 88.52% | $9,132 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 77.62% | 74.82% | $7,762 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 73.06% | 70.26% | $7,306 / yr |
| 🇬🇧 UK ISA | 0% | 91.32% | 88.52% | $9,132 / yr |
| 🇬🇧 UK Taxable | 8.75% | 83.33% | 80.53% | $8,333 / yr |
| 🇨🇦 TFSA | 0% | 91.32% | 88.52% | $9,132 / yr |
| 🇨🇦 CA Taxable | 25% | 68.49% | 65.69% | $6,849 / yr |
| 🇦🇺 Super (pension) | 15% | 77.62% | 74.82% | $7,762 / yr |
| 🇦🇺 AU Taxable | 30% | 63.92% | 61.12% | $6,392 / yr |
| 🇩🇪 DE Taxable | 26.375% | 67.23% | 64.43% | $6,723 / yr |
| 🇫🇷 FR Taxable | 30% | 63.92% | 61.12% | $6,392 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ETTX pays quarterly — 4 times per year. Next ex-div: TBD.
How ETTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ETTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2022-07-08 | 7,598,814 | $2.20 | $16.72M | ||
| J-Other | 2022-07-11 | 24,858 | $3.11 | $77.3K | ||
| J-Other | 2022-07-11 | 6,465 | $3.74 | $24.2K | ||
| J-Other | 2022-07-11 | 50,000 | $4.94 | $247.0K | ||
| U-Tender | 2022-07-07 | 39,596 | $2.20 | $87.1K | ||
| D-Return | 2022-07-11 | 150,000 | — | — | ||
| J-Other | 2022-07-11 | 98,700 | $2.44 | $240.8K | ||
| J-Other | 2022-07-11 | 69,970 | $3.74 | $261.7K | ||
| U-Tender | 2022-07-07 | 56,072 | $2.20 | $123.4K | ||
| J-Other | 2022-07-11 | 325,755 | $2.44 | $794.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ETTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Entasis Therapeutics Holdings Inc. (ETTX) is currently trading at $2.19, 33% below its 52-week high. The current dividend yield is 91.32% based on an annual payout of $2.00 per share.
Entasis Therapeutics Holdings Inc. (ETTX) is a healthcare stock currently trading at $2.19 with a dividend yield of 91.32%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →